WORCESTER, Mass., April 20, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com) announced today that Antigen Express, Inc., its wholly-owned immunotherapeutics subsidiary, has presented recent pre-clinical findings on a novel immunotherapeutic vaccine for human papilloma virus (HPV)-induced cancers. The study, entitled: ``Ii-Key/HPV16 E7 hybrid peptide vaccine for HPV16+ cancers,'' was presented by Dr. Minzhen Xu, Ph.D., the Antigen Express Vice-President of Biology, at the 100th Annual Meeting of the American Association for Cancer Research (http://www.aacr.org) in Denver, CO, being held from April 18-22, 2009.
